Published • loading... • Updated
DEA Moves to Ban Kratom-Related Compounds Sold in Consumer Products
The emergency action targets compounds sold in consumer products and follows research linking them to opioid-like effects and addiction risk.
- The Drug Enforcement Administration classified three semisynthetic kratom-related compounds—mitragynine pseudoindoxyl, MGM-15, and MGM-16—as Schedule I substances on an emergency basis for two years.
- Attorney General Todd Blanche said the Justice Department acted because compounds are "being manufactured and sold in consumer products, often under labels that obscure their true risks." The move follows a year of federal targeting of kratom products.
- Clinicians report increasing patient dependencies on kratom variants. Dr. Myles Jen Kin, medical director at the Recovery Centers of America's Massachusetts location, said he now sees "10 cases a week," up from roughly one weekly a year ago.
- Dr. Caleb Banta-Green, a research professor at the University of Washington's School of Medicine, worries the classification will force dependent customers into withdrawal or dangerous alternatives while blocking research into potential medicinal uses.
- Natural kratom remains regulated in at least 22 states, with eight—including Alabama, Connecticut, Ohio, and Vermont—having banned the substance, illustrating how regulatory frameworks for the herb vary significantly across the United States.
Insights by Ground AI
37 Articles
37 Articles
Missouri kratom company destroys $10M in products after DEA crackdown
Kansas City-based CBD American Shaman says it destroyed $10 million worth of product this week after the U.S. Drug Enforcement Administration placed a potent kratom-related opioid manufactured by the company into Schedule I of the Controlled Substances Act.
·Washington, United States
Read Full Article
Coverage Details
Total News Sources37
Leaning Left1Leaning Right0Center34Last UpdatedBias Distribution97% Center
Bias Distribution
- 97% of the sources are Center
97% Center
C 97%
Factuality
To view factuality data please Upgrade to Premium
